Eli Lilly to write off schizophrenia drug

Share this article:

Eli Lilly's dog days of summer continue. The company said Wednesday that it was dropping its Phase III schizophrenia drug because a futility analysis of the second Phase III study of the drug was “unlikely to be positive in its primary efficacy endpoints if enrolled to completion."

The news followed the company's July announcement that a Phase II study involving use of the drug, mGLU2/3, as an add-on therapy with atypical psychotics also missed its targets.

This setback marks the third ding for the company's pipeline and in-line products in a very brief span. Lilly said Monday that its anti-platelet drug Effient failed in an attempt to show an edge over generic Plavix. That news was preceded by Friday's announcement that the experimental Alzheimer's drug solanezumab failed to show progress on two criteria -- global and cognitive function -- but may continue to be tested.

Lilly said the aborted Phase III development of mGLU2/3 will surface as a third-quarter R&D charge of between $25 million and $30 million, pretax. The company said the charge will not affect its guidance for 2012.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...